Mineralys Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 12, 2025
MLYS$15.81+3.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
The information required by this item is incorporated by reference from our 2025 Proxy Statement under the caption “Executive Compensation and Director Compensation.”
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.